Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 16 (cancelled).

17(original). An immediate release pharmaceutical formulation comprising from 950 to 1300 or 1900 to 2600 mg amoxycillin, in combination with pharmaceutically acceptable excipients or carriers.

18(original). An immediate release pharmaceutical tablet formulation according to claim 17 comprising 1000 mg ±5% amoxycillin in combination with pharmaceutically acceptable excipients or carriers.

19(original). An immediate release pharmaceutical formulation according to claim 17 in the form of a single dose sachet comprising 2000, 2250 or 2500 mg ±5% amoxycillin or the corresponding half quantities thereof, in combination with pharmaceutically acceptable excipients or carriers.

20(original). An immediate release formulation according to claim 17 in the form of a dispersible tablet or a chewable tablet, effervescent dispersible or effervescent chewable tablet comprising 2000, 2250, or 2500 mg amoxycillin or the corresponding half quantities thereof, in combination with a chewable base and, if effervescent, an effervescent couple, and other pharmaceutically acceptable carrier or excipient.

Claims 21 to 43 (cancelled).

44(original). A pharmaceutical formulation comprising 1000 mg ±5% amoxycillin, in combination with pharmaceutically acceptable excipients or carriers.

45(original). The pharmaceutical formulation according to claim 44 in which the amoxycillin is present as a mixture of amoxycillin trihydrate and sodium amoxycillin in a ratio of 3:1 to 1:3.

46(original). A pharmaceutical formulation comprising amoxycillin in which amoxycillin is provided as a mixture of amoxycillin trihydrate and sodium amoxycillin in a ratio of from 3:1 to 1:3.

47(original). The pharmaceutical formulation according to claim 46 in which the ratio of amoxycillin trihydrate and sodium amoxycillin is from 3:2 to 2:3.

48(original). A pharmaceutical formulation comprising a pharmaceutically acceptable soluble salt of amoxycillin in a slow release phase which further comprises a release retarding excipient which is a pharmaceutically acceptable organic acid present in a molar ratio of from 100:1 to 1:10 (amoxycillin salt to organic acid).

49(original). The pharmaceutical formulation according to claim 48 in which the molar ratio is 50:1 to 1:5.

50(original). The pharmaceutical formulation according to claim 48 in which the organic acid is citric acid.

51(original). The pharmaceutical formulation according to claim 48 in which the soluble salt of amoxycillin is sodium amoxycillin.

52(original). A kit comprising an immediate release formulation comprising amoxycillin, and a slow release formulation comprising amoxycillin (and no potassium clavulanate).

53(original). Compacted granules for use in a pharmaceutical formulation comprising amoxycillin, a diluent/compression aid, and an organic acid (if amoxycillin is present as a soluble salt thereof) or a release retarding polymer or a mixture thereof.

54(original). Compacted granules for use in a pharmaceutical formulation comprising sodium amoxycillin, microcrystalline cellulose, and an organic acid or a release retarding polymer or a mixture thereof.

55(original). The process for preparing compacted granules according to claim 54 which process comprises the steps of blending together sodium

amoxycillin, microcrystalline cellulose, and organic acid or release retarding polymer or mixture thereof, compacting the blend and then milling.

Claims 56 to 58 (Cancelled).